Bayer (FRA:BAYN) has been assigned a €67.00 ($77.91) target price by equities research analysts at Berenberg Bank in a research report issued on Monday, April 1st, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. Berenberg Bank’s price target would indicate a potential upside of 8.87% from the stock’s previous close.
BAYN has been the subject of several other reports. Societe Generale set a €65.00 ($75.58) price target on shares of Bayer and gave the stock a “neutral” rating in a report on Wednesday, March 27th. UBS Group set a €110.00 ($127.91) price objective on Bayer and gave the company a “buy” rating in a report on Monday, February 4th. DZ Bank restated a “buy” rating on shares of Bayer in a report on Monday, March 11th. Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the company a “buy” rating in a report on Friday, January 18th. Finally, Kepler Capital Markets set a €84.00 ($97.67) price objective on Bayer and gave the company a “buy” rating in a report on Thursday, December 6th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of €82.07 ($95.42).
Shares of FRA:BAYN traded up €0.50 ($0.58) during trading on Monday, hitting €61.54 ($71.56). 4,672,473 shares of the company were exchanged. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.